These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 22394596)
21. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study. Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119 [TBL] [Abstract][Full Text] [Related]
22. Clinical remission of primary aggressive CD8+ cutaneous T-cell lymphoma after pralatrexate infusion. Kerdel FA; Styperek AR; Maini A JAMA Dermatol; 2014 Mar; 150(3):320-2. PubMed ID: 24452280 [No Abstract] [Full Text] [Related]
23. Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma. Foss FM Expert Opin Drug Metab Toxicol; 2011 Sep; 7(9):1141-52. PubMed ID: 21726160 [TBL] [Abstract][Full Text] [Related]
25. Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment. Merdin A; İskender D; Ulu BU; Doğan M; Çakar MK; Dal MS; Altuntaş F Medicine (Baltimore); 2019 Jul; 98(30):e16482. PubMed ID: 31348254 [TBL] [Abstract][Full Text] [Related]
26. Pralatrexate (Folotyn) for peripheral T-cell lymphoma. Med Lett Drugs Ther; 2010 Jul; 52(1342):55-6. PubMed ID: 20622807 [No Abstract] [Full Text] [Related]
27. Pralatrexate Monitoring Using a Commercially Available Methotrexate Assay to Avoid Potential Drug Interactions. McPherson JP; Vrontikis A; Sedillo C; Halwani AS; Gilreath JA Pharmacotherapy; 2016 Feb; 36(2):e8-e11. PubMed ID: 26809959 [TBL] [Abstract][Full Text] [Related]
28. Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma. Shimanovsky A; Dasanu CA Expert Opin Pharmacother; 2013 Mar; 14(4):515-23. PubMed ID: 23409799 [TBL] [Abstract][Full Text] [Related]
29. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Duvic M; Talpur R; Ni X; Zhang C; Hazarika P; Kelly C; Chiao JH; Reilly JF; Ricker JL; Richon VM; Frankel SR Blood; 2007 Jan; 109(1):31-9. PubMed ID: 16960145 [TBL] [Abstract][Full Text] [Related]
30. A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma. Dunn TJ; Dinner S; Price E; Coutré SE; Gotlib J; Hao Y; Berube C; Medeiros BC; Liedtke M Br J Haematol; 2016 Apr; 173(2):253-9. PubMed ID: 27040320 [TBL] [Abstract][Full Text] [Related]
31. A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma. Mould DR; Sweeney K; Duffull SB; Neylon E; Hamlin P; Horwitz S; Sirotnak F; Fleisher M; Saunders ME; O'Connor OA Clin Pharmacol Ther; 2009 Aug; 86(2):190-6. PubMed ID: 19474785 [TBL] [Abstract][Full Text] [Related]
32. Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study. Hong X; Song Y; Huang H; Bai B; Zhang H; Ke X; Shi Y; Zhu J; Lu G; Liebscher S; Cai C Target Oncol; 2019 Apr; 14(2):149-158. PubMed ID: 30904980 [TBL] [Abstract][Full Text] [Related]
33. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618 [TBL] [Abstract][Full Text] [Related]
34. Trimetrexate in relapsed T-cell lymphoma with skin involvement. Sarris AH; Phan A; Duvic M; Romaguera J; McLaughlin P; Mesina O; King K; Medeiros LJ; Rassidakis GZ; Samuels B; Cabanillas F J Clin Oncol; 2002 Jun; 20(12):2876-80. PubMed ID: 12065565 [TBL] [Abstract][Full Text] [Related]
35. Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review. Stewart JR; Desai N; Rizvi S; Zhu H; Goff HW Eur J Dermatol; 2018 Dec; 28(6):764-774. PubMed ID: 30591425 [TBL] [Abstract][Full Text] [Related]
36. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center. Querfeld C; Mehta N; Rosen ST; Guitart J; Rademaker A; Gerami P; Kuzel TM Leuk Lymphoma; 2009 Dec; 50(12):1969-76. PubMed ID: 19860617 [TBL] [Abstract][Full Text] [Related]